Came from the AFR article... so why is this company valued at $300m+ yet, from my understanding, hasn't actually commenced FDA clinical trials? Is the pre clinical data that impressive that the likelihood of success is so high?
I have literally had a quick glance at it so I could be incorrect with my interpretation, just seems like a high valuation for a company that hasn't yet begun FDA trials...
DurAVR and AVR in the AFR today! (Plus Bioshares), page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.27 |
Change
0.360(6.09%) |
Mkt cap ! $97.17M | |||
| Open | High | Low | Value | Volume |
| $5.93 | $6.30 | $5.91 | $107.9K | 17.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | $6.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.27 | 200 | 1 |
View Market Depth
| Last trade - 15.42pm 27/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |